The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesWB: Use at a concentration of 1-5 µg/ml. IF/ICC: Use at a concentration of 10 µg/ml. IHC-P: Use at a concentration of 3 µg/ml.
Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.
FunctionInvolved in the hydrolysis of N-acylated or N-acetylated amino acids (except L-aspartate).
Tissue specificityExpression is highest in kidney, strong in brain and weaker in placenta and spleen.
Involvement in diseaseDefects in ACY1 are the cause of aminoacylase-1 deficiency (ACY1D) [MIM:609924]. ACY1D results in a metabolic disorder manifesting with encephalopathy, unspecific psychomotor delay, psychomotor delay with atrophy of the vermis and syringomyelia, marked muscular hypotonia or normal clinical features. Epileptic seizures are a frequent feature. All affected individuals exhibit markedly increased urinary excretion of several N-acetylated amino acids.
Sequence similaritiesBelongs to the peptidase M20A family.
Aminoacylase 1 antibody (ab54960) used in immunofluorescence at 10ug/ml on HeLa cells.
IHC-P - Aminoacylase 1 antibody (ab54960)
Aminoacylase 1 antibody (ab54960) used in immunohistochemistry at 3ug/ml on formalin fixed and paraffin embedded human malignant lymphoma, diffuse large B tissue.
Western blot - Aminoacylase 1 antibody (ab54960)
Predicted band size : 46 kDa Aminoacylase 1 antibody (ab54960) at 1ug/lane + K-562 cell lysate at 25ug/lane.
References for Anti-Aminoacylase 1 antibody (ab54960)
This product has been referenced in:
Wei X et al. Proteomics-based identification of the tumor suppressor role of aminoacylase 1 in hepatocellular carcinoma. Cancer Lett351:117-25 (2014).
Read more (PubMed: 24846301) »
Jin GZ et al. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values. BMC Cancer13:161 (2013).
Read more (PubMed: 23537217) »